Notice |
How to write your comments onto a webpage
[2]
| 2016.07.06 | 운영자 | 2016.11.20 | 18194 |
Notice |
How to Upload Pictures in webpages
| 2016.07.06 | 운영자 | 2018.10.19 | 32352 |
Notice |
How to use Rich Text Editor
[3]
| 2016.06.28 | 운영자 | 2018.10.19 | 5929 |
Notice |
How to Write a Webpage
| 2016.06.28 | 운영자 | 2020.12.23 | 43843 |
504 |
Olympic Spirit
[3] | 2016.08.08 | 황규정*65 | 2016.08.09 | 52 |
503 |
[Medical] Longevity Gene
[2] | 2019.04.23 | 이한중*65 | 2019.04.23 | 52 |
502 |
Flying Penguins
[1] | 2019.04.01 | 온기철*71 | 2019.04.01 | 52 |
501 |
[Medical] Safety Comparison, Apixaban vs Rivaroxaban
[1] | 2019.03.24 | 이한중*65 | 2019.03.24 | 52 |
500 |
참말같은 거짓말
| 2019.03.12 | 온기철*71 | 2019.03.13 | 52 |
499 |
한국; 전쟁과 평화
[2] | 2019.01.28 | 온기철*71 | 2019.01.29 | 52 |
498 |
Saturn May Be Losing Its Rings
| 2018.12.18 | 이한중*65 | 2018.12.18 | 52 |
497 |
한미일 공동기자회견 at Camp David
[3] | 2023.08.18 | 온기철*71 | 2023.08.21 | 51 |
496 |
발해; 중국, 일본, 한국 누구의 땅이었던가?
| 2022.05.19 | 온기철*71 | 2022.05.19 | 51 |
495 |
Hitler를 연상하게 하는 시진핑
[2] | 2022.02.09 | 온기철*71 | 2022.02.09 | 51 |
494 |
[EPL]손흥민, ESPN 선정 베스트11…살라와 함께 좌·우 공격수
[1] | 2021.12.31 | 황규정*65 | 2021.12.31 | 51 |
493 |
경직된 일본 정치
[3] | 2021.09.29 | 온기철*71 | 2021.09.30 | 51 |
492 |
신라 삼국통일은 역사가 아니다. 일본의 Propaganda 이다.
[3] | 2021.09.21 | 온기철*71 | 2021.09.22 | 51 |
491 |
“Superhuman” Immunity To Covid-19
[1] | 2021.09.07 | 이한중*65 | 2021.09.07 | 51 |
490 |
Nipah virus outbreak in India
[3] | 2021.09.07 | 이한중*65 | 2021.09.07 | 51 |
489 |
아프가니스탄, 영국, 러시아, 조선, 일본; Great Game
[2] | 2021.08.26 | 온기철*71 | 2021.08.27 | 51 |
488 |
한국조력 아프간 372명 한국으로
[7] | 2021.08.24 | 온기철*71 | 2021.08.26 | 51 |
487 |
What happens in Cuba could happen in North Korea
[1] | 2021.07.14 | 온기철*71 | 2021.07.14 | 51 |
486 |
Socrates, the Founder of Western Philosophy
[2] | 2021.06.07 | 이한중*65 | 2021.06.07 | 51 |
485 |
D10 선진 민주국가 10개국 동맹 한국가입과 통일
[4] | 2021.05.17 | 온기철*71 | 2021.05.20 | 51 |
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
List of authors.
Abstract
BACKGROUND
Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.
METHODS
We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018–2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.
RESULTS
A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.
CONCLUSIONS
Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.)(NEJM July 8, 2020)